How are we doing in achieving target LDL-cholesterol levels in the high-risk population in Slovakia: retrospective study
Authors:
Štefan Tóth 1,2; Daniel Pella 3
Authors‘ workplace:
SLOVACRIN, LF Univerzity Pavla Jozefa Šafárika v Košiciach
1; MEDIPARK, LF Univerzity Pavla Jozefa Šafárika v Košiciach
2; II. kardiologická klinika LF Univerzity Pavla Jozefa Šafárika a Východoslovenský ústav srdcových a cievnych chorôb, a. s., Košice
3
Published in:
AtheroRev 2022; 7(2): 110-115
Category:
Clinical Studies
Overview
Introduction: Despite significant progress in the management of cardiovascular (CV) diseases, they represent the most common cause of morbidity and mortality. LDL-cholesterol (LDL-C) reduction is a basic pillar of primary as well as secondary prevention of heart disease. The Aim of this study was to monitor LDL-C concentrations in patients at very high CV risk and to determine the prevalence of patients reaching the LDL-C target values. Methodology: This project took place in the form of a retrospective analysis of anonymized LDL-C values from 2017–2019 from the data of cooperating laboratory with nationwide operations. Overall, patients with a diagnosis of an acute coronary syndrome (ACS), stroke and a general patient with a very high CV risk were included. The LDL-C target values were evaluated based on the then valid ESC/EAS 2016 recommendations. Results: A total of 220,657 LDL-C results from 72,039 patients were obtained. In patients with ACS, LDL-C target values were achieved by only 8–9 % of patients in each year of follow-up. Up to 6–9 % of patients have LDL-C levels ≥ 4.9 mmol/L. In the case of patients with stroke, only 9–10 % of patients achieved target values and 7–8 % had levels ≥ 4.9 mmol/L. In the group with very high CV risk, only 7 % of patients reached the target levels and 7–8 % had extremely high LDL-C values ≥ 4.9 mmol/L. In the case of the application of the new ESC/EAS 2019 recommendations, the target levels were reached by only 2–3 % of patients. Conclusion: Based on the results of the analysis, we found that up to 90 % of patients at very high CV risk do not reach the target LDL-C values. These patients remain at high risk for further CV events and would benefit significantly from intensified hypolipidemic therapy.
Keywords:
dyslipidemia – cardiovascular risk – target values – LDL-cholesterol – retrospective analysis
Sources
1. Libby P. The changing landscape of atherosclerosis. Nature 2021; 592(7855): 524–533. Dostupné z DOI: <http://dx.doi.org/10.1038/s41586–021–03392–8>.
2. Marchio P, Guerra-Ojeda S, Vila JM et al. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev 2019; 2019:8563845. Dostupné z DOI: <http://dx.doi.org/10.1155/2019/8563845>.
3. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.
4. Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008; 117(19): 2458–66. Dostupné z DOI:<http://dx.doi.org/10.1161/CIRCULATIONAHA.108.77374>
5. Nicholls SJ, Puri R, Anderson T et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 2016; 316(22):2373–2384. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.16951>.
6. Gitt AK, Lautsch D, Ferrieres J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158–66. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.013>.
7. Studencan M, Pella D, Bramlage P et al. Clinical characteristics and management of hyperlipoproteinemia in patients with chronic coronary heart disease in Slovakia. Arch Med Sci 2021. Dostupné z DOI: <https://doi.org/10.5114/aoms/122017>.
8. Kováčová M, Hubáček JA, Mrózová L, Hroncová D. LDL-C cholesterol u pacientov s dyslipidémiami: retrospektívna analýza lokálnych údajov o LDL-C získaných za roky 2017 – 2019. InovaHealth: Bratislava 2021.
9. World Health Organization. Global Health Observatory data. Cholesterol. Dostupné z WWW: <http://www.who.int/gho/ncd/risk_factors/cholesterol_prevalence/en/>.
10. Fulcher J, O‘Connell R, Voysey M. Cholesterol Treatment Trialists‘ Collaboration. Efficacy and safety of LDL‐lowering therapy among men and women: meta‐analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385(9976): 1397–405. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61368–4>.
11. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532–2561 Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(16)31357–5>.
12. Riečanský I. K súčasnému stavu a problémom slovenskej kardiológie. Med Monitor 2004; 2: 10–12.
13. Baráková A. Choroby obehovej sústavy – vybrané informácie z údajov zdravotníckej štatistiky za rok 2003. Cardiol 2005; 14(3): K/C74–76. Dostupné z WWW: <http://www.cardiology.sk/casopis/305/pdf/07_infoSKS_02.pdf>.
14. Bruthans J, Cífková R, Lánská V et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21(7): 829–839. Dostupné z DOI: <https://doi.org/10.1177/2047487312469476>.
15. Bandosz P, O’Flaherty M, Drygas W et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ 2012; 344: d8136. Dostupné z DOI: <http://dx.dpo.org/10.1136/bmj.d8136>.
16. Joensen AM, Joergensen T, Lundbye-Christensen S et al. Explaining trends in coronary heart disease mortality in different socioeconomic groups in Denmark 1991–2007 using the IMPACTSEC model. Dostupné z DOI: PLoS One 2018; 13(4): e0194793. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0194793>.
17. Psota M, Bandosz P, Goncalvesova E et al. Explaining the decline in coronary heart disease mortality rates in the Slovak Republic between 1993–2008. PloS One 2018; 13(1):e0190090. Dostupné z DOI: <http://dx.doi.org/0.1371/journal.pone.0190090>.
18. Catapano, AL, Graham I, De Backer G et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw272>.
19. Pella D, Pecen L, Műllerová J et al. Sme úspešní pri dosahovaní cieľových hodnôt pre LDL-cholesterol u pacientov liečených statínmi? Výsledky prieskumu DYSIS I. Slovenská republika. Int Med 2015.
20. Gitt AK, Lautsch D, Ferrières J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158–166. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.013>.
21. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
22. Čaprnda M, Hencel J, Farkašovský J et al. Dosiahnutie cieľových hodnôt LDL cholesterolu efektívnejšou dávkou atorvastatínu 30 mg v praxi všeobecného lekára. Via Pract 2015; 12(5): 213–216.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2022 Issue 2
Most read in this issue
- Benefits of GLP-1 receptor agonists therapy for patients with cardiovascular disease
- Lysosomal acid lipase deficiency – differential diagnosis and treatment options in 2022
- How are we doing in achieving target LDL-cholesterol levels in the high-risk population in Slovakia: retrospective study
- Lifelong exposure and trajectories of the risk factors – a new direction in prediction of CVD risk